NIKKEI 225
39,660.69 +487.54 (+1.24%) HANG SENG
18,069.75 -3.15 (-0.02%) CRUDE OIL
81.20 +0.37 (+0.46%) GOLD FUTURES
2,328.10 -2.70 (-0.12%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,677.82 +370.26 (+0.77%)
REGN Dec 2025 990.000 put
| Previous close | 103.10 |
| Open | N/A |
| Bid | 72.00 |
| Ask | 81.90 |
| Strike | 990.00 |
| Expiry date | 2025-12-19 |
| Day's range | 103.10 - 103.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
